Enhancing Pediatric Pain Management in Portuguese Emergency Departments: Progress and Challenges (2007-2018)

By João L. Carapinha

April 29, 2025

Pain assessment in Portuguese PEDs has seen substantial progress from 2007 to 2018. The adoption of local protocols and pain scales increased from 52% to 93%, based on a recently published study. However, pediatric pain management remains inadequate for mild to moderate pain, with only 22% of facilities consistently administering analgesia. Treatment for severe pain and opioid usage appears sufficient. Procedural sedation and analgesia have increased but are not universally practiced. Alarmingly, 88% of staff members recognize the need for enhanced training.

Advancements in Pain Assessment Practices

The implementation of pain assessment protocols and pain scales has increased dramatically:

  • Local pain management protocols rose from 52% in 2007 to 93% in 2018.
  • Pain scale usage reached 100% by 2018, showing a comprehensive approach.
  • By 2018, nurses became the primary pain assessors in all hospitals.

This improvement reflects the application of national guidelines after Portugal’s National Plan Against Pain (2001) and pediatric-specific guidelines.

Ongoing Challenges in Effective Pain Treatment

Despite assessment advancements, pain management still faces obstacles. More hospitals treat mild to moderate pain at least 50% of the time (91% in 2018 vs. 57% in 2007). Yet only 22% always provide analgesia, down from 43% in 2007. Analgesia for procedures remains underused: i) venipuncture analgesia is rarely given (83% never used it in 2018), ii) lumbar puncture analgesia saw no improvement, iii) fracture reduction and wound suture pain management improved. Use increased from 52% to 83%, but ethical concerns persist. Forced immobilization was reported in 26% of hospitals.

Importance of Addressing Pediatric Pain

Pain affects over 60% of PED admissions, making it critical in emergency care. Despite global awareness, pediatric pain management remains inadequate. Untreated pain can cause immediate anxiety and delayed care, plus long-term emotional harm and chronic pain risks. Since Portugal’s National Plan Against Pain (2001) and pediatric guidelines (2010), policy efforts have improved. However, local implementation varies.

The WHO states pain relief is a fundamental right and that inadequate management is substandard care. WHO guidelines recommend multimodal pediatric pain management, blending pharmacological and non-pharmacological methods.

Implications for Healthcare Quality and Economics

Cost Implications of Inadequate Pain Management

Poor pain management may lead to longer emergency stays, more return visits, extra resources for complications, higher long-term costs.

Necessity for Training and Resource Allocation

The study shows a demand for training (88% of staff seek more). Effective programs require staff education, protocol development, quality monitoring, and medication availability.

Future Research Directions

To address gaps, healthcare systems should:

  1. Standardize Protocols: Universal pain assessment and triage protocols.
  2. Invest in Education: Targeted training on opioid fears and symptom masking.
  3. Promote Quality Improvements: Regular audits and feedback.
  4. Allocate Resources Wisely: Ensure analgesic access in all PEDs.
  5. Encourage Research: Study cost-effectiveness and long-term outcomes.

While progress has been made in Portuguese PEDs, more work is needed to improve pain management. For details, see the original study here.

Reference url

Recent Posts

Novartis Gains Approval for Groundbreaking Malaria Treatment for Infants

By Rene Pretorius

July 30, 2025

In this article we review Swissmedic's approval of Novartis' Coartem Baby. It is the first malaria treatment for infants under 4.5 kilograms. This novel formulation addresses a critical gap in antimalarial care. Existing treatments were unsuitable due to dosing and metabolism concerns in young in...
ViiV Healthcare Licensing: Expanding Access to Long-Acting HIV Treatment in Low-Income Countries
ViiV Healthcare has expanded its voluntary licensing agreement with the Medicines Patent Pool. The update now includes access to long-acting injectable cabotegravir (CAB LA) for HIV treatment. This allows generic manufacturers to supply the therapy in 133 low- and middle-income countries (LMICs)....
FDA Approval of ANZUPGO: A New Chronic Hand Eczema Treatment

By João L. Carapinha

July 29, 2025

The FDA has approved ANZUPGO® (delgocitinib cream), a major advancement. It is the first topical treatment for moderate-to-severe chronic hand eczema (CHE) in adults, developed by LEO Pharma. This pan-JAK inhibitor targets multiple inflammatory pathways (